Advised Alpine Bird Manufacturing on the sale of its 50% limited partnership interest in Action Manufacturing LP (Australasia’s largest vehicle specialiser) to Tourism Holdings Limited.  

Advised Clinician Holdings on its latest investment round, raising US$5.4m at a pre-money valuation of more than US$40m.

Advised the investors on the latest investment round for Helius Therapeutics – an additional $15m invested in Series D, (increasing total investment to date to more than $45m).

Advised the lead investor syndicate on the latest investment round for Nyriad Limited which raised in excess of $33m of new equity (inclusive of note conversion).

Advising Covid-19 Vaccine Corporation (and its investors) on capital raising and licensing arrangements ($4.3m invested to date).

Advised Clinician Holdings on its investment round to raise approx. US$2.4m from NZ investors and Australian and Singapore VCs.

Advised Massey University on the sale of its ‘Ferri Pro’ technology (which combats iron deficiency) to Nestle.

Advised the investor consortium in relation to their NZ$15m investment in leading medical cannabis start-up, Helius Therapeutics.

Acted for Fergus Software in relation to aggregate investments of $A3.5m by an Australian venture capital fund and a large Australian corporate.

Andrew was appointed to the board of high growth financial services company Enable-Me – www.enableme.co.nz